In life sciences, three structures are emerging for AI-enabled research transactions — but each raises legal and strategic questions, requiring adaptations to existing deal frameworks…. By: Goodwin
Previous Story
Proprietary Data and Specialist AI: The Evolving Market in Life Sciences Transactions
Next Story
[Video] The Briefing: Fake People, Real Ads New York’s New Rules for AI Generated Performers
